ClinicalTrials.gg

Program

SHR-4602

A development code. Also written as “SHR-4602 for injection”.

Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jul 18, 20244 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine42 open or runningphase 2since Jul 18, 2024Apr 6, 2023Apr 2027phase 2 · NCT06704828

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05819684 · 133 planned · China
  2. Jul 18, 2024Phase 2 study in HER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsNCT06516926 · 11 enrolled · China
  3. Aug 15, 2024Phase 1 study in HER2-expressing or HER2-mutated Locally or Metastatic Solid TumorsNCT06560138 · Australia
  4. Nov 22, 2024Phase 2 study in Advanced Solid TumorsNCT06704828 · 20 planned · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06704828

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06704828Advanced Solid Tumors · China2Not yet recruitingApr 202720
NCT06560138HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors · Australia1WithdrawnDec 14, 20250
NCT06516926HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors · China2TerminatedMay 23, 202511
NCT05819684Advanced Solid Tumor · China1RecruitingMay 30, 2025133

How it is read

Names in the registry

  • “SHR-4602”, 3 entries
  • “SHR-4602 for injection”, 1 entry

Codes read as this program: SHR4602.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.